Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.

Autor: Moros A; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain. Electronic address: sandra.moros@hipra.com., Prenafeta A; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain. Electronic address: antoni.prenafeta@hipra.com., Barreiro A; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Perozo E; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Fernández A; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Cañete M; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., González L; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Garriga C; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Pradenas E; IrsiCaixa, AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain., Marfil S; IrsiCaixa, AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain., Blanco J; IrsiCaixa, AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Catalonia, Spain., Cebollada Rica P; Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain., Sisteré-Oró M; Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain., Meyerhans A; Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain; ICREA (Catalan Institution for Research and Advanced Studies), Pg. Lluís Companys 23, 08010 Barcelona, Spain., Prat Cabañas T; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., March R; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain., Ferrer L; HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 Aug 07; Vol. 41 (35), pp. 5072-5078. Date of Electronic Publication: 2023 Jul 16.
DOI: 10.1016/j.vaccine.2023.07.008
Abstrakt: The continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (RBD) of the Beta variant of SARS-CoV-2 fused in tandem with the equivalent domain of the Alpha variant, with its immunogenicity, safety and efficacy previously demonstrated in mouse models. In the present study, we immunized pigs with different doses of PHH-1V in a prime-and-boost scheme showing PHH-1V to exhibit an excellent safety profile in pigs and to produce a solid RBD-specific humoral response with neutralising antibodies to 7 distinct SARS-CoV-2 variants of concern, with the induction of a significant IFNγ + T-cell response. We conclude that PHH-1V is safe and elicits a robust immune response to SARS-CoV-2 in pigs, a large animal preclinical model.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Edward Pradenas reports a relationship with Gilead Sciences Inc that includes: travel reimbursement. Julia Blanco reports a relationship with Gilead Sciences Inc that includes: speaking and lecture fees and travel reimbursement. Julia Blanco reports a relationship with Merck Sharp & Dohme UK Ltd that includes: consulting or advisory and funding grants. Julia Blanco reports a relationship with Albajuna Therapeutics that includes: equity or stocks. Julia Blanco reports a relationship with Grifols SA that includes: funding grants. Julia Blanco reports a relationship with Nesapor that includes: funding grants. Paula Cebollada Rica reports a relationship with Laboratorios HIPRA S.A. that includes: funding grants. Marta Sistere reports a relationship with Laboratorios HIPRA S.A. that includes: funding grants. Andreas Meyerhans reports a relationship with Laboratorios HIPRA S.A. that includes: funding grants. Alexandra Moros reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Antonio Prefaneta reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Antonio Barreiro reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Eva Perozo reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Alex Fernandez reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Manuel Canete reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Luis Gonzalez reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Carme Garriga reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Teresa Prat Cabanas reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Ricard March reports a relationship with Laboratorios HIPRA S.A. that includes: employment. Laura Ferrer reports a relationship with Laboratorios HIPRA S.A. that includes: employment.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: